PubMed=8121182; DOI=10.1002/jso.2930550209
Yoshida A., Asaga T., Masuzawa C., Kawahara S., Yanoma S., Harada M., Okamoto T.
Production of cytokines by thyroid carcinoma cell lines.
J. Surg. Oncol. 55:104-107(1994)
PubMed=8176927; DOI=10.1002/jso.2930550308
Yoshida A., Asaga T., Masuzawa C., Kawahara S.
Alteration of tumorigenicity in undifferentiated thyroid carcinoma cells by introduction of normal chromosome 11.
J. Surg. Oncol. 55:170-174(1994)
PubMed=9177455; DOI=10.1016/S0304-3835(97)04742-3
Satake S., Sugawara I., Watanabe M., Takami H.
Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines.
Cancer Lett. 116:33-39(1997)
PubMed=16924234; DOI=10.1038/sj.onc.1209899
Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
Oncogene 26:1178-1187(2007)
PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)
Patent=US8029793
Yoshida A., Yanoma S., Hirose F.
Methods for inhibiting cell proliferation.
Patent number US8029793, 04-Oct-2011
PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)
PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)